SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing ...
A PDUFA target date of November 4, 2024 has been assigned for this application. The Food and Drug Administration (FDA) has accepted the New Drug Application for DFD-29 (minocycline hydrochloride ...
he NICE-Wide Prioritisation Board met on 15 September 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback